Statins, super-statins and cholesterol absorption inhibitors

IDrugs

Volumn 6, Issue 5, 2003, Pages 458-463

  Brousseau, Margaret E ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Cholesterol absorption; Ezetimibe; Lipoprotein; Rosuvastatin; Statin

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; BETA CAROTENE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABSORPTION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CORONARY RISK; DIABETES MELLITUS; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; PLASMA; REFERENCE VALUE; REVIEW; SIDE EFFECT; STROKE;

ABSORPTION; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 0037869355     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Rose G, Hamilton PS, Keen H, Reid DD, McCartney P, Jarrett RJ: Myocardial ischemia, risk factors and death from coronary heart-disease. Lancet (1977) 1:105-109.
2. American Heart Association: 1998 Heart and Stroke Statistical Update. American Heart Association, Dallas, TX, USA (1998).
3. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary heart disease: A meta-analysis of randomized controlled trials. J Am Med Assoc (1999) 282:2340-2346. Trials in which participants were randomized to statin or control treatment for at least four years, and clinical disease or death was the primary outcome were included in this meta-analysis (n = 5). It was concluded that statin-associated CHD risk reduction in women was similar to that of men, while that of the elderly was similar to the middle-aged.
4. Schaefer EJ, Brousseau ME: Perspectives: Benefits of reducing low-density lipoprotein cholesterol concentrations to < 100 mg/dl. Prev Cardiol (2000) 3:136-139.
5. Illingworth DR, Sexton GJ: Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest (1984) 74:1972-1978.
6. Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, Tobert JA, Bacon SR, Bolognese JA, Frost PH, Lamkin GE et al: Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: A multicenter study. Ann Intern Med (1987) 107:609-615.
7. The Lovastatin Study Group II: Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: A multicenter study. J Am Med Assoc (1986) 256:2829-2834.
8. Grundy SM, Vega GL: Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res (1985) 26:1464-1475.
9. Ara Y, Ramakrishnan R, Ginsberg HN: Lovastatin therapy reduces low density lipoprotein ApoB levels in subjects with combined hyperlipidemia by reducing the production of ApoB-containing lipoproteins: Implications for the pathophysiology of ApoB production. J Lipid Res (1990) 31:567-582.
10. Illingworth DR, O'Malley JP: The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism (1990) 39:403-409.
11. Vega GL, East C, Grundy SM: Lovastatin therapy in familial dysbetalipoproteinemia: Effects on kinetics of apolipoprotein B. Atherosclerosis (1988) 70:131-143.
12. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolemia. N Engl J Med (1995) 333:1301-1307.
13. Downs JR, Beere PA, Whitney E, Clearfield M, Weis S, Rochen J, Stein EA, Shapiro DR, Langendorfer A, Gotto AM Jr: Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol (1997) 80:287-293.
14. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. J Am Med Assoc (1998) 279:1615-1622.
15. Scandinavian Simvastatin Survival Study Group: Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol (1993) 71:393-400.
16. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389. This is the first study to evaluate the effects of cholesterol-lowering with a statin (simvastatin) on morbidity and mortality in men and women with CHD.
17. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T et al: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation (1998) 97:1453-1460. This report revealed that the reduction in major coronary events observed within the treatment group of the 4S trial was highly correlated with on-treatment levels and changes from baseline in total and LDL cholesterol, indicating that the beneficial effect of simvastatin observed in this group of CHD patients was determined mainly by the magnitude of the change in LDL-C.
18. Sacks FM, Pfeffer MA, Moye L, Brown LE, Hamm P, Cole TG, Hawkins CM, Braunwald E: Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The Cholesterol and Recurrent Events trial (CARE). Am J Cardiol (1991) 68:1436-1446.
19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med (1996) 335:1001-1009.
20. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation (1998) 97:1446-1452.
21. The LIPID Study Group: Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) Study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol (1995) 76:474-479.
22. The LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med (1998) 339:1349-1357.
23. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet (2002) 360:7-22.
24. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet (2002) 360:23-33.
25. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM et al: The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). Am J Cardiol (1999) 84:1192-1197.
26. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM et al: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet (2002) 360:1623-1630. This was the first study to carefully explore the benefits of statin therapy in terms of CHD risk reduction in the elderly.
27. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M: Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitor. Am J Cardiol (2001) 87:28B-32B.
28. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ: No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor. J Clin Pharmacol (2002) 42:1116-1121.
29. Chapman MJ, McTaggart F: Optimizing the pharmacology of statins: Characteristics of rosuvastatin. Atheroscler Suppl (2002) 2:33-36.
30. Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol (2001) 88:504-508. The results of two dose-ranging studies with rosuvastatin were described in this report. Relative to placebo, rosuvastatin significantly reduced LDL-C concentrations in a dose-dependent manner in hypercholesterolemic patients.
31. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW: Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J (2002) 144:1044-1051. This study compared the effects of rosuvastatin and atorvastatin in reducing LDL-C and achieving LDL-C goals in patients with primary hypercholesterolemia.
32. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson H: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hyper-cholesterolemia. Am J Cardiol (2002) 89:268-275.
33. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H: Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk (2001) 8:383-390.
34. Stein E, Strutt KL, Miller E, Southworth H: ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol (2001) 37(Suppl A):292A.
35. Stein E, Strutt KL, Miller E, Southworth H: Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolemia. Atherosclerosis (2001) 2:90-91.
36. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, Mabuchi H, Tushima M, Sasaki J, Ogawa N, Goto Y: A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis (2002) 162:373-379. In this multicenter, phase II trial conducted in Japan, pitavastatin lowered LDL-C by 38% in hyperlipidemic patients.
37. Noji Y, Higashikata T, Inazu A, Nohara A, Ueda K, Miyamoto S, Kajinami K, Takegoshi T, Koizumi J, Mabuchi H: Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis (2002) 163:157-164.
38. Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, Davis HR Jr: In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of active metabolites of SCH48461. J Pharmacol Exp Ther (1997) 283:157-163.
39. Rosenblum SB, Huynh T, Afonso A, Davis HR Jr, Yumibe N, Clader JW, Burnett DA: Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyp henyl)-2-azetidinone (SCH 58235): A designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem (1998) 41:973-980.
40. Van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, Davis HR Jr: Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol (2000) 129:1748-1754.
41. Van Heek M, Compton DS, Davis HR: The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol (2001) 415:79-84.
42. Davis HR Jr, Pula KK, Alton KB, Burrier RE, Watkins RW: The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitors in dogs. Metabolism (2001) 50:1234-1241.
43. Davis HR Jr, Watkins RW, Compton DS, Cook JA, Hoos L, Pula K, Van Heek M: The cholesterol absorption inhibitor ezetimibe (SCH58235) and lovastatin synergistically lower plasma cholesterol and inhibit the development of atherosclerosis. J Am Coll Cardiol (2000) 35(Suppl 2A):252A.
44. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, LeBeaut AP, Yang B, Mellers LE: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies. Clin Ther (2001) 23:1209-1230. The results of a multicenter, placebo-controlled, randomized trial, which examined the effects of ezetimibe on plasma lipoproteins in patients with primary hypercholesterolemia, are reported.
45. Ezzet F, Wexler D, Statkevich P, Kosoglou T, Patrick J, Lipka L, Mellars L, Veltri E, Batra V: The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol (2001) 41:943-949.
46. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol (2002) 90:1092-1097.
47. Kosoglou T, Meyer I, Cutler DL, Musiol B, Yang B, Zhu Y, Maxwell SE, Affrime MB, Veltri EP: Pharmacodynamic interaction between the selective cholesterol absorption inhibitor ezetimibe and lovastatin. Third International Conference on Coronary Artery Disease - From Prevention to Intervention, Lyon, France (2000).
48. Kosoglou T, Seiberling M, Statkevich P, Cutlre DL, Yang B, Anderson L, Maxwell SE, Affrime MB: Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. J Am Coll Cardiol (2001) 37:229A.
49. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol (2002) 40:2125-2134.